Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2014-08-31 Major Shareholding Noti…
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
Form 604 Change Substantial Shareholding Mr H Rosen 5 pages 1.5MB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Substantial Shareholding Notice: Form 604' and discusses a change in interest of shares by an executive director due to dilution from a capital raising. It references Form 604, which is a notice of change in substantial shareholding. The content focuses on shareholding changes rather than financial results, management changes, or other report types. The document length is 3530 characters, which is relatively short and consistent with a notification rather than a full report. Therefore, this document fits the category of Major Shareholding Notification (MRQ).
2014-08-31 English
June 2014 App 4D Half Yearly Report and Financial Report 23 pages 7.9MB
Regulatory Filings
2014-08-26 English
General Meeting Results 1 page 383.5KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a short announcement (2262 characters) reporting the results of resolutions passed at a General Meeting (GM) of shareholders. It details voting outcomes on securities issuance and placement. There is no detailed financial data, no full report, and no indication that this is a proxy solicitation or AGM materials. The content matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at general meetings. The document is not a full report but a voting result announcement, so it is classified as DVA with high confidence.
2014-08-25 English
First IND Enabling Study for TPM Oxymorphone Completed 3 pages 51.4KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Phosphagenics Limited regarding the completion of a pharmacokinetic study related to their TPM/Oxymorphone patch. It discusses study results, clinical trial phases, and future plans for FDA IND submission. The content is an update on clinical development progress and study outcomes rather than a financial report, regulatory filing, or management discussion. It does not contain financial statements, voting results, or executive changes. The document is a corporate announcement about a clinical study completion and development update, fitting best under a general regulatory announcement category rather than a specific financial or governance report. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (6498 characters) and detailed content support this classification with high confidence.
2014-08-10 English
Allotment of Share Purchase Plan New Shares 2 pages 191.5KB
Capital/Financing Update Classification · 95% confidence The document is a company announcement from Phosphagenics Limited dated 6 August 2014. It announces the completion of a Share Purchase Plan (SPP) offering to shareholders, including the issuance of 37,500,000 new ordinary shares and the resulting total shares on issue. The content focuses on equity capital raising and share issuance details. There are no financial statements, detailed financial analysis, or regulatory certifications present. The document is relatively short (3564 characters) and is clearly an announcement of a capital raising event through share issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2014-08-05 English
Share Purchase Plan Closed Oversubscribed 2 pages 50.1KB
Capital/Financing Update Classification · 95% confidence The document is an announcement from Phosphagenics Limited regarding the closure and oversubscription of a Share Purchase Plan (SPP), raising A$3 million as part of a larger equity capital raising. It details the allocation of shares, the use of funds for clinical trial programs, and includes forward-looking statements about the company's business and risks. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The content focuses on fundraising and capital structure changes through share issuance. Therefore, this document fits the category of a Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement of a report nor a regulatory filing or certification. Confidence is high due to clear focus on capital raising and share issuance details.
2014-08-04 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.